Mito Stack Stack Protocol

Stack Overview

The Mito Stack is the most ambitious protocol in the Kalios stack library. Three compounds targeting mitochondrial function from three mechanistically distinct angles: MOTS-c (the software — signals cells to build more and better mitochondria), SS-31/elamipretide (the hardware — stabilizes cardiolipin on the inner mitochondrial membrane so existing mitochondria run efficiently), and NAD+ (the fuel — the coenzyme all of them rely on). SS-31 became FDA-approved in September 2025 (Forzinity, for Barth syndrome), making it the only approved compound in this stack; MOTS-c and NAD+ remain off-label.

Who this is for: adults 40+ with declining energy, exercise tolerance, and cognitive clarity that lab-workup has traced to mitochondrial dysfunction (or suspected it). Users with post-viral fatigue syndromes. Post-chemotherapy recovery. Metabolic syndrome not fully responsive to lifestyle. Longevity-focused users committed to a science-dense but evidence-evolving protocol. Endurance athletes interested in mitochondrial density.

Who this is NOT for: beginners — this is a third or fourth protocol, not a starter. Users with active or recent malignancy (SS-31 stabilizes mitochondria in all cells including potentially transformed ones; NAD+ and MOTS-c are less concerning but still cautioned). Users expecting rapid dramatic changes — mitochondrial remodeling is measured in months, not weeks. Anyone treating "tiredness" without a workup — mitochondrial dysfunction should be suspected after other causes are excluded.

Honest framing: SS-31 is the only FDA-approved compound in this stack (narrow indication: Barth syndrome). MOTS-c has growing preclinical and human biomarker data but no Phase 3 program. NAD+ precursors (NR, NMN) have multiple small RCTs but no definitive longevity outcomes. The three-compound combination has no clinical trial and exists as a mechanistically coherent hypothesis. The stack is built on good science; how much of that science translates to clinical benefit in healthy adults is still being established.

The Compounds

Why they pair: mitochondrial function has three layers. You need enough mitochondria (MOTS-c: biogenesis), each one working efficiently (SS-31: cardiolipin / ETC integrity), with enough NAD+ to power the chemistry (NAD+ precursors). Addressing one layer alone underperforms addressing all three. This is the cleanest mechanistic argument for any stack in the Kalios library — three non-overlapping interventions on one organelle system.

Synergy & Mechanism

• Biogenesis (MOTS-c) — AMPK activation → PGC-1α → mitochondrial biogenesis transcriptional program. More mitochondria per cell.
• Efficiency (SS-31) — Cardiolipin stabilization → tighter ETC organization → less electron leak → more ATP per unit substrate, less ROS as byproduct.
• Substrate (NAD+) — NAD+ is the electron acceptor in glycolysis, TCA cycle, fatty acid β-oxidation. More NAD+ → more substrate processing capacity. Also required for sirtuin activity (longevity regulators) and PARP-mediated DNA repair.
• Complementary timescales — NAD+ effect is fastest (days to weeks). SS-31 effect is mid-range (weeks to months). MOTS-c effect via biogenesis is slowest (months). Using all three gives coverage across the timescales mitochondrial remodeling operates on.
• ROS feedback loop break — Aged mitochondria produce more ROS, which damages cardiolipin, which reduces ATP, which increases ROS. SS-31 interrupts this loop at the cardiolipin step; MOTS-c reduces cellular demand on the damaged mitochondria by building new ones; NAD+ supports the efficient ones.
• No receptor competition — Three independent mechanisms. No compound downregulates another's target. Rare among stacks.

Dosing Protocol & Reconstitution

The Mito Stack is almost always run as three separate vials. Pre-blends are impractical because the compounds have different optimal dosing cadences (SS-31 daily-ish, MOTS-c 2–3x/week, NAD+ 3–5x/week). Community SubQ NAD+ is the most common form of "NAD+" in this stack — oral precursors (NMN, NR) are an option but deliver less tissue NAD+ per dose and are covered in the Substitutions section.

Two sequencing approaches (this is the distinguishing feature of the Mito Stack):

• "Bachmeyer" approach — MOTS-c first. Start MOTS-c alone for weeks 1–2 to drive biogenesis signaling before layering SS-31 and NAD+. Rationale: new mitochondria first, then support them. Layer SS-31 at week 3, NAD+ at week 4. Less common but has a loyal following.
• Community consensus — SS-31 first. Start SS-31 alone for weeks 1–4 to stabilize existing mitochondrial membranes. Then layer MOTS-c at week 3–4 and NAD+ throughout or from week 1. Rationale: fix the existing hardware before asking for more of it. This is the more common approach as of 2026.
• Simultaneous start — All three from week 1. Fastest to full effect; hardest to attribute response to any single compound if something goes wrong.

Reconstitution specifics:

• SS-31 10 mg vial + 1 mL BAC water → 10 mg/mL. 5 mg = 50 units on U-100 syringe; 10 mg = 100 units (full syringe volume). Some users split 10 mg into two 50-unit injections at separate sites to reduce stinging.
• MOTS-c 10 mg vial + 1 mL BAC water → 10 mg/mL. 5 mg = 50 units; 10 mg = 100 units. Alternative: 2 mL BAC for 5 mg/mL (5 mg = 100 units) if you prefer larger measurement volumes.
• NAD+ 500 mg vial + 5 mL BAC water → 100 mg/mL. 100 mg = 100 units; 200 mg = 200 units (split into two 100-unit injections at different sites). NAD+ SubQ stings — slow push and site rotation help.
• NAD+ IV is a clinic procedure: 250–500 mg diluted into 500 mL saline, infused over 4–6 hours. Faster infusion = severe flushing, nausea, chest pressure. This is the most clinic-time-intensive component if included.

→ Use the Kalios Peptide Calculator for exact syringe units

Sample Weekly Schedule

Community consensus protocol (SS-31 first 2–4 weeks, then layer MOTS-c, NAD+ throughout). Shown: full steady-state week once all three are active (roughly week 4+).

Weekly totals: SS-31 50 mg (5 doses), MOTS-c 20 mg (2 doses), NAD+ 300 mg SubQ (3 doses). Vial consumption: ~1 SS-31 vial/week, ~1 MOTS-c vial/5 weeks, ~1 NAD+ 500 mg vial/5 weeks.

Heavier variant: SS-31 daily 5x/week plus MOTS-c 3x/week (Mon/Wed/Fri) plus NAD+ 5x/week (200 mg). Bigger mitochondrial coverage, higher injection burden. Weekly totals: SS-31 50 mg, MOTS-c 30 mg, NAD+ 1 g SubQ.

Bachmeyer sequencing variant (MOTS-c first, weeks 1–2): start with MOTS-c 5–10 mg 3x/week alone for weeks 1–2. Layer SS-31 in week 3 and NAD+ in week 4. From week 4 onward, the steady-state schedule matches above.

IV NAD+ upgrade: replace SubQ NAD+ with weekly clinic infusion 250–500 mg over 4–6 hours (typically Sunday). Much stronger acute NAD+ elevation; substantially more clinic time.

Oral-precursor variant: swap SubQ NAD+ for oral NMN 500–1,000 mg daily. Adequate for general longevity; less potent for post-viral fatigue or documented mitochondrial dysfunction.

Cycle Structure & Timing

• Loading (weeks 1–4) — Full dosing on all three compounds. Most users will see the early NAD+ and SS-31 effects here (energy, sleep quality, small cognitive improvements).
• Mid-cycle (weeks 5–8) — Continued full dosing. MOTS-c biogenesis effects start to show on exercise tolerance and metabolic markers (fasting glucose, HbA1c trend).
• Consolidation (weeks 9–12) — Peak response window. All three mechanisms at full expression. Objective markers (VO2 max, fasting glucose, inflammation markers) should show changes.
• Washout (weeks 13–16, minimum 4 weeks) — Off SS-31 and MOTS-c completely. Oral NMN can continue at maintenance (500 mg/day) through washout if desired — it's not a pulse-dose compound in the same way.
• Annual cadence — 2 cycles per year is a typical community pattern for longevity users. Chronic-condition users (post-viral, primary mitochondrial disorders) may run more frequent or continuous protocols under clinical supervision.
• Timing with training — MOTS-c overlaps mechanistically with exercise-induced mitochondrial biogenesis. Inject on training days rather than rest days, pre-workout if convenient. Anecdotal benefit; not trial-proven.
• Bloodwork timing — Baseline before starting: CMP, HbA1c, fasting insulin, lipid panel, hsCRP. Mid-cycle (week 6) for trend. End-of-cycle (week 12) for peak response.

What to Expect — Timeline

• Week 1 — NAD+ effects are typically the fastest. Users sometimes report improved AM energy and mental clarity within 3–5 days of starting NMN or after a first IV NAD+ infusion. SS-31 and MOTS-c are still building up.
• Week 2–3 — Sleep quality often improves — multi-factorial (NAD+ supports sirtuin-mediated circadian function; SS-31 reduces nocturnal ROS-driven disruption). Subjective cognitive clarity for responders. Some loss of pre-exercise fatigue.
• Week 4–6 — Objective changes emerge. Fasting glucose often drops modestly (MOTS-c insulin sensitivity). Exercise tolerance measurable increase. Some users report modest fat-mass reduction around the waist without dietary change.
• Week 6–9 — Primary response window. All three compounds at maximum effect. Users with baseline mitochondrial-dysfunction-type fatigue (post-viral, chronic fatigue spectrum) often describe the clearest benefit here.
• Week 9–12 — Consolidation. Peak gains. Biomarker improvements become clinically interpretable.
• Washout (13–16) — NAD+ effects attenuate within 2–3 weeks off. SS-31 effects persist longer (weeks to months, because of cumulative cardiolipin stabilization). MOTS-c biogenesis gains (more mitochondria per cell) persist longest — structural remodeling.
• Non-responders — Real. Mitochondrial-dysfunction baseline matters: users with genuine mitochondrial decline tend to respond best; users already-optimized have less room to improve and often report subtle or no changes. If you're 30, athletic, and sleeping well, this stack probably has less to offer than it does for a 55-year-old with post-viral fatigue.

Side Effects & Monitoring

• MOTS-c — Generally well-tolerated. Occasional mild fatigue in the first week (may reflect cellular metabolic reprogramming). Rare GI upset. No meaningful long-term safety signal at community doses.
• SS-31 — Injection site reactions (more common than other peptides; sometimes visible local redness). Occasional headache. Rare dizziness. In Phase 2/3 trials at 40 mg daily, safety profile has been favorable.
• NAD+ IV — Flushing, nausea, chest tightness — usually from too-fast infusion rate. Slow the drip. Occasional post-infusion fatigue. "Foggy" feeling during infusion is common.
• NMN / NR oral — Well-tolerated at community doses. Rare GI upset. Theoretical cancer-risk concerns at supraphysiologic chronic dosing — the data is insufficient to quantify, but moderation is wise.
• Combined — No unique additive side effects documented. The main concern with the combination is injection burden and compounding regulatory status, not toxicity.
• Methyl group depletion (NMN/NR specific) — Both precursors consume methyl groups during metabolism. Some users supplement methylfolate or TMG to offset. Evidence for clinical relevance in healthy users is modest.
• Cancer concern — SS-31 stabilizes mitochondria in all cells, including transformed ones. NAD+ supports cell metabolism including cancer cell metabolism. MOTS-c is less direct but promotes cellular proliferation. Active or recent malignancy is a contraindication for this stack.
• Baseline monitoring — CMP + CBC (standard), fasting glucose + HbA1c + fasting insulin (MOTS-c effect), hsCRP (inflammation), lipid panel, vitamin D, vitamin B12 (relevant for NMN/NR metabolism), ferritin. Consider ALT/AST (high-dose IV NAD+ has occasionally produced mild transient transaminitis).
• Functional monitoring — Resting heart rate trend, HRV (if you track), VO2 max if you're willing to measure. These are the most objective readouts for mitochondrial function improvement.
• Red flags — New persistent chest pain, fainting, severe persistent headache, unexplained weight loss, new neurological symptoms. Stop and evaluate.

Substitutions & Alternatives

• NMN oral in place of IV NAD+ — The simplest substitution. Oral precursors reliably raise intracellular NAD+ in humans per multiple RCTs. IV NAD+ produces faster and higher peak elevation; oral produces sustained modest elevation. Most of the stack's NAD+ benefit is capturable orally.
• NR instead of NMN — NR has deeper RCT evidence (Martens, Airhart, Elhassan). NMN has a larger 2020s user base. Either is reasonable; NR is slightly better-evidenced.
• Drop SS-31 — The stack works as a two-compound MOTS-c + NAD+ protocol. Loses the cardiolipin-specific mechanism; keeps biogenesis + fuel. Reasonable simplification.
• Drop MOTS-c — SS-31 + NAD+ is another common two-compound variant. Focus shifts from "grow new mitochondria" to "fix existing ones + fuel them." Works if you exercise enough to drive biogenesis naturally.
• Add Urolithin A — Small-molecule mitophagy activator (clears damaged mitochondria so biogenesis produces net-new healthy ones). Emerging evidence in humans. Pairs cleanly with Mito Stack mechanism. Oral.
• Add GHK-Cu — Pickart's gene-expression data includes mitochondrial biogenesis gene upregulation. Complementary to MOTS-c; not a primary mitochondrial intervention.
• CoQ10 + alpha-lipoic acid + acetyl-L-carnitine — The traditional mitochondrial-support supplement trio. Broadly available OTC; modest evidence. Reasonable first step before committing to the Mito Stack.
• Exercise + caloric restriction / TRF — The non-pharmacologic mitochondrial-function interventions with the deepest evidence. These amplify any Mito Stack significantly and should precede peptide escalation.

Practical User Notes

• Don't start with the Mito Stack. It is a third or fourth protocol. Run simpler stacks first; understand your individual response to GH-axis or repair-axis peptides; then layer in the mitochondrial compounds.
• Oral NAD+ precursor first, IV later. Oral NMN or NR gives a substantial portion of the NAD+-elevation benefit with a dramatically simpler protocol. IV NAD+ is worth adding only if oral precursors underperform for you specifically — not as a default.
• SS-31 injection site matters. SS-31 reports more injection-site reactions than most peptides. Rotate sites diligently, use 29G+ needles, inject slowly. Some users prefer IM to SubQ despite the increased technique difficulty.
• Sequence matters on injection day. MOTS-c and SS-31 can be injected minutes apart; separate sites. NAD+ IV is a whole-afternoon commitment and dominates its day.
• Pair with exercise. MOTS-c specifically reinforces exercise-induced mitochondrial biogenesis; SS-31 benefits are amplified in actively working muscle. Sedentary users will get less out of this stack than active ones.
• Fasting or time-restricted eating amplifies NAD+ effects. NAD+ salvage pathways are upregulated in fasted states. If you can run a 14–16 hour daily fast, NAD+ precursors work harder.
• Alcohol is antagonistic. Alcohol metabolism consumes NAD+. Chronic heavy alcohol use nullifies this stack's NAD+ investment.
• Methyl donors matter for NMN/NR chronic use. TMG 1–2 g/day or methylated B-complex prevents methyl depletion. A simple supplemental addition.
• Source discipline. SS-31 research-chemical varies in purity; Forzinity is pharmaceutical-grade but rarely accessible off-label. MOTS-c is synthesized cleanly but newer to the market. NAD+ IV preparation requires pharmacy-grade sourcing from a clinic. Independent COAs for all three.
• Bloodwork matters more than subjective feel. HbA1c, fasting insulin, inflammatory markers, VO2max — these are the objective readouts. Subjective "I feel better" is unreliable across a 12-week mitochondrial remodeling timeframe.
• Active cancer is a contraindication. SS-31 stabilizes mitochondria in cancer cells too; NAD+ supports cancer cell metabolism; MOTS-c promotes proliferation. Don't run this stack with active or recent malignancy.
• Reassess the protocol quarterly. Decide whether the objective response you're seeing justifies continued commitment. Most users who sustain long-term use have documented mitochondrial dysfunction baseline, not general longevity curiosity.

Who Should Consider This Stack

The Mito Stack is not a first protocol. Indication is concentrated in adults with documented or strongly suspected mitochondrial dysfunction rather than general longevity curiosity.

• Documented mitochondrial dysfunction — Primary mitochondrial myopathy, MELAS, Leigh syndrome, or Barth syndrome (SS-31/Forzinity has the approved indication here). Clinical-grade stack rationale.
• Post-viral fatigue syndromes — Long COVID, post-EBV chronic fatigue, post-SARS. Mitochondrial dysfunction is implicated in the pathophysiology; the Mito Stack is a mechanism-targeted hypothesis.
• Post-chemotherapy recovery — Many chemotherapeutics cause mitochondrial injury. Recovery protocols targeting mitochondrial function have plausibility; active malignancy is a contraindication.
• Metabolic syndrome not fully responsive to lifestyle — Insulin resistance and impaired fat oxidation reflect mitochondrial dysfunction at the cellular level. The stack addresses that layer while lifestyle fixes address the upstream cause.
• Endurance athletes and masters athletes — Mitochondrial density is the rate-limiting factor for endurance; MOTS-c's exercise-mimetic biology is most relevant to this population.
• Longevity-focused adults 45+ with baseline biomarker evidence of mitochondrial decline — Reduced VO2max, rising fasting glucose, declining grip strength, worsening sleep quality with normal other labs. Evidence is evolving; expectations should be calibrated.
• Not for beginners — Complex three-compound injection protocol with sophisticated biology. Start with simpler protocols (individual peptide use or lifestyle interventions) before committing to the Mito Stack.
• Not for active cancer — SS-31 stabilizes mitochondria in all cells including transformed ones; NAD+ supports cell metabolism including cancer cell metabolism; MOTS-c promotes cellular proliferation. Hard contraindication.

Objective Readouts to Track

Subjective response is unreliable across a 12-week mitochondrial remodeling timeframe. Objective biomarker tracking is how you know the stack is working.

• Fasting insulin + HOMA-IR — The cleanest direct readout of AMPK-axis engagement from MOTS-c and the SS-31 cardiolipin benefit. Baseline and at 8 and 12 weeks.
• Fasting glucose + HbA1c — Expect modest improvement in users with baseline insulin resistance. Baseline and quarterly.
• hsCRP — Mitochondrial dysfunction drives chronic low-grade inflammation. Improvement in hsCRP is a sensitive readout of net-mitochondrial-function change.
• VO2max or 6-minute walk distance — Most objective fitness-capacity readout. Baseline and 12 weeks. VO2max improvements of 2–4 mL/kg/min are clinically meaningful.
• Resting heart rate and heart-rate variability (HRV) — Continuous wearable data. Declining RHR and rising HRV over 8–12 weeks is the signature of improved autonomic / cardiovascular / mitochondrial health.
• Grip strength — Sensitive and cheap. Baseline and quarterly. Declining grip strength in an adult over 55 is a negative mortality predictor; stable or improving grip is positive.
• Sleep architecture (deep sleep + REM time) — NAD+ sirtuin support and SS-31 ROS reduction both correlate with improved sleep architecture. Wearable or polysomnography data.
• DEXA body composition — Lean mass gain, visceral fat reduction. Baseline and 12 weeks. Changes often subtle but real in responders.
• Lipid panel including particle size (NMR) — Mitochondrial fat oxidation improvements affect the lipid particle size distribution before they affect total cholesterol. Specialized but informative.
• Symptom diary (for post-viral / chronic fatigue users) — Validated instruments (Chalder Fatigue Scale, DePaul Symptom Questionnaire) baseline and at 6, 12 weeks provide the patient-reported outcome that matters most in this population.

Regulatory Status & Access

Related Compounds

People researching the Mito Stack often also look at these:

Next Steps

References

References cover the individual components (SS-31 FDA-approved as Forzinity; MOTS-c and NAD+ precursor RCTs) and the mechanistic framework. No trial has studied the three-compound combination.

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459.
2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109.
3. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. PMID: 24117165.
4. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221. PMID: 29523644.
5. Reid Thompson W, DeCost B, Pillar N, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome (TAZPOWER). Genet Med. 2021;23(3):471-478. PMID: 33129823.
6. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478.
7. Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459. PMID: 29211728.
8. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728. PMID: 31412242.
9. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596.
10. Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257. PMID: 31572171.
11. Kim SJ, Mehta HH, Wan J, et al. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (Albany NY). 2018;10(6):1239-1256. PMID: 29886452.
12. Stealth BioTherapeutics. Forzinity (elamipretide) prescribing information. FDA approval September 2025 — Barth syndrome.

→ Use the Kalios Peptide Calculator for exact syringe units